VC Deals
Mechio Inc. (dba Motiv), a San Francisco-based micro-wearables startup, has raised more than $8.6 million in Series A funding, according to a regulatory filing. Kleiner Perkins Caufield & Byers was joined by return backer Granite Ventures
Clear Labs, developer of a database that will index foods based on genetic analysis, has raised $6.5 million in Series A funding. Backers include Khosla Ventures, Felicis Capital, HBR Genomics and Passport Capital
Omada Health, a San Francisco-based provider of group-based “digital therapeutic” programs for chronic disease prevention, has raised $48 million in Series C funding. Norwest Venture Partners led the round, and was joined by Humana Inc., Providence Health & Services, GE Ventures, dRx Capital and return backers U.S. Venture Partners and Andreessen Horowitz
Oscar Health, a New York-based health insurance startup, has raised $32.5 million in new funding fromGoogle Capital at a $1.75 billion valuation
Alector LLC, a San Francisco-based developer of immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, has raised $32 million in Series C funding. MRL Ventures led the round, and was joined by OrbiMed, Polaris Partners, Google Ventures, Topspin Partners and Mission Bay Capital
DJ HealthUnion Systems Corp., a provider of digital hospital solutions in China, has raised US$12.5 million in funding from HAO Capital
Kyruus, a Boston-based provider of physician network optimization software, has raised $25 million in new VC funding. New Leaf Venture Partners led the round, and was joined by Providence Health & Services, Leerink Capital Partners, McKesson Ventures and return backers Venrock, Highland Capital Partners, Lux Capital, and Fidelity Biosciences
Ativa Medical, a St. Paul, Minn.-based developer of a diagnostic micro lab for physicians, has raised $15 million in Series B funding. Backers include Ping An Ventures, Hermed Capital, LabCorp, Dian Diagnostics and GIMDx
Creo Medical, a British developer of an electrosurgery platform, has raised $8.45 million in new VC funding.Pentax Medical was joined by return backers Finance Wales and the Angel CoFund
Clover Health, a San Francisco-based health insurance startup, has raised $100 million in Series A equity and debt financing. First Round Capital led the round with a $4 million commitment (the largest initial investment in the firm’s history). Other backers include Athyrium Capital Management. First Round’s Josh Kopelman and Flatiron Health co-founder Nat Turner will join the Clover board of directors
Body Labs, a 2.5-year-old, New York-based 3-D body visualization technology, has raised $4.1 million in new funding, shows an SEC filing flagged by VentureWire. The company had previously raised $2.2 million from FirstMark Capital and New York Angels
CureVac, a 15-year-old, Tübingen, Germa-based company that’s developing new, messenger-RNA therapies, has raised $225 million, including from the Bill & Melinda Gates Foundation. (The money isn’t new but it’s newly public information.) It’s also opening an office in Cambridge, Ma
Alector, a two-year-old, San Francisco-based company that’s developing immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, has raised $32 million in Series C funding led by MRL Ventures, with participation from OrbiMed, Polaris Partners,Google Ventures, Topspin Partners and Mission Bay Capital
Catamaran Ventures invested in Coverfox as part of a series B round of US$14 million led by Accel USA, Accel India, and SAIF Partners
PE Deals
ABRY Partners has agreed to acquire International Medical Group Inc., an Indianapolis-based healthcare insurance company, from Galen Partnersand Altaris Capital Partners. No financial terms were disclosed
Edge BioSystems Inc., a Gaithersburg, Md.-based portfolio company ofStoneCalibre LLC, has acquired the Ion Chromatography business ofTransgenomic Inc.(Nasdaq: TBIO). No financial terms were disclosed. The San Jose, Calif.-based business will be renamed Concise Separations, and operate as a division of Edge Bio
Tricast Inc., a Milwaukee-based pharmacy benefit data monitoring and analytics company, has raised an undisclosed amount of private equity funding from Blue Heron Capital and Brook Venture Partners
Berkshire Partners is in advanced talks to acquireAffordable Care, a Raleigh, N.C.-based denture services provider currently owned by American Capital, according to Reuters. The deal would be worth north of $800 million (including debt)
Advent International has acquired a 13% stake in Fleury SA (Brazil: FLRY3), the second-largest diagnostic services provider in Brazil, from a physician group that will retain another 28.3% position
Serum Institute of India Ltd., a privately-held vaccine maker, is in talks to sell up to a 10% stake to unidentified private equity firms at an enterprise valuation of around $12 billion
IPO Deals
Dimension Therapeutics Inc., a Cambridge, Mass.-based developer of liver-directed treatments for genetic disorders, has filed for a $115 million IPO. It plans to trade on the Nasdaq under ticker symbol DMTX, with Goldman Sachs and Citigroup serving as lead underwriters. The company reports a $15.4 million net loss on $3.3 million in revenue for the first half of 2015. It has raised over $120 million in VC funding from New Leaf Venture Partners, Fidelity Biosciences,OrbiMed Advisors, Jennison Associates, Partner Fund Management, RA Capital Management, Rock Springs Capital and Tourbillon Global Ventures
Regenexbio Inc., a Rockville, Md.-based gene therapy company, has narrowed its IPO pricing range from$17-$19 to $22 per share. It still plans to offer 5.56 million shares, and now would have an initial market cap of around $541 million, were it to price at its target. The company plans to trade on the Nasdaq under ticker symbol RGNX, with Morgan Stanley, BofA Merrill Lynch and Piper Jaffray serving as co-lead underwriters. Regenexbio has raised over $100 million in VC funding, including a $70.5 million in Series D round earlier this year. Shareholders include Venrock (9.5% pre-IPO stake), Brookside Capital (9.2%), Deerfield Management (6.1%), Fidelity (5.7%), GlaxoSmithKline (5.7%), Vivo Capital, Janus Capital Management, Jennison Associates, Perceptive Advisors, QVT Financial, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management, Foresite Capital Management and RTW Investments
SynCardia Systems Inc., a Tucson, Ariz.-based developer of an artificial heart, has set its IPO terms to 2.5 million shares being offered at between $10 and $12 per share. It would have an initial market cap of approximately $86 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol AHT, with Roth Capital Partners serving as underwriter. SynCardia reports an $18.6 million net loss on $8.7 million in revenue for the first six months of 2015. Shareholders include SWK Holdings (30.4% pre-IPO stake), Athyrium Capital Management, Highway 12 Ventures and Delta Electronics Capital
Penumbra Inc., an Alameda, Calif.-based maker of medical devices for those who have experienced strokes and other neurovascular diseases, raised $120 million in its IPO. The company priced 4 million shares at $30 per share, compared to plans to offer 3.8 million shares at between $25 and $28 a piece. Its initial market cap is over $900 million. The company will trade on the NYSE under ticker symbol PEN, while J.P. Morgan and BofA Merrill Lynch served as co-lead underwriters. Penumbra reports a $169,000 net loss on $81 million in revenue for the first six months of 2015, compared to $1.6 million in net income on $58 million in revenue for the year-earlier period. Fidelity holds an 11.6% pre-IPO stake
Mirna Therapeutics Inc., an Austin, Texas-based developer of microRNA therapeutics for oncology, has set its IPO terms to 4.65 million shares being offered at between $13 and $15 per share. It would have an initial market cap of around $233.5 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol MIRN, with Citigroup and Leerink Partners serving as co-lead underwriters. Mirna Therapeutics has raised around $83 million in VC funding, from firms like Sofinnova Ventures (17.83% pre-IPO stake), New Enterprise Associates (17.83%), Pfizer Ventures (15.01%), Eastern Capital (6.39%), Osage University Partners and Correlation Ventures
Nabriva Therapeutics AG, an Austria-based developer of antibiotics to treat serious infections, raised $92 million in its IPO. The company priced 9 million shares at $10.25 per share, compared to original plans to offer 6 million shares at between $15 and $17 per share. It will trade on the Nasdaq under ticker symbol NBRV, while Leerink Partners and RBC Capital Markets served as lead underwriters. Shareholders include HBM Healthcare Investments (17.9% pre-IPO stake), Vivo Capital (17.8%), OrbiMed Advisors (16.1%), Phase4 Ventures (14.3%), The Wellcome Trust (11%), Global Life Sciences Ventures (8.3%), Hatteras Venture Partners, Tavistock Life Science, Kreos Capital and Novartis Ventures
Other Deals
Applied DNA Sciences Inc. (Nasdaq: APDN) has acquired the assets ofVandalia Research Inc., a Huntington, West Va.-based DNA sequencing startup, for $1.5 million in cash. Vandalia had been backed by Mountaineer Capital and the West Virginia Jobs Investment Trust Board
Practo, an Indian search portal that matches physicians with patients, has acquired Insta Health, an Indian provider of hospital management systems and electronic medical records software, for $12 million. Practo has raised $120 million in VC funding (including a recent $90m Series C round) from Tencent, Google Capital, Yuri Milner, Sofina, Altimeter Capital, Sequoia Capital and Matrix Partners. Insta Health was backed by Inventus Capital Partners
Shire PLC (Nasdaq: SHPG) is thinking about ways it can sweeten its takeover offer for biotech companyBaxalta (NYSE: BXLT), which last month rejected a $30.6 billion all-stock bid
Tricast Inc., a Milwaukee-based pharmacy benefit data monitoring and analytics company, has raised an undisclosed amount of private equity funding from Blue Heron Capital and Brook Venture Partners
Qualcomm (Nasdaq: QCOM) has acquired Capsule Technologie, a French provider of medical device integration and clinical data management solutions. No financial terms were disclosed. Sellers include JMI Equity and Bulger Capital Partners
Dentsply International Inc. (Nasdaq: XRAY) has agreed to acquire fellow dental products maker Sirona Dental Systems Inc. (Nasdaq: SIRO) in an all-stock deal valued at around $5.5 billion. The combined company would be worth around $13.3 billion and it expected to have more than $900 million in combined EBITDA. Under terms of the deal, Sirona Dental holders will receive 1.8142 shares of Dentsply stock for each Sirona share
Persivia, a Lowell, Mass.-based provider of chronic care management solutions, has acquired IHM Services Co., a Burlington, Mass.-based provider of clinical intelligence solutions for hospitals. No financial terms were disclosed
Sun Pharmaceutical Industries Ltd., a listed Indian drugmaker, has agreed to acquire InSite Vision Inc. (OTC BB: INSV), an Alameda, Calif.-based maker of specialty ophthalmic products, for approximately $48 million
Amgen (Nasdaq: AMGN) has agreed to acquire Dezima Pharma, a Dutch cardiovascular drug developer. The deal includes a $300 million up-front cash payment, and upwards of $1.25 billion in milestone-based earn-outs. Dezima Pharma has raised VC funding from BioGeneration Ventures, Forbion Capital Partners and New Science Ventures
Perrigo (NYSE: PRGO), an Ireland-based drugmaker, is asking shareholders to reject a $27 billion cash and stock takeover offer from Mylan (Nasdaq: MYL), saying it undervalues the company
Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg
#healthtech #asia